(NASDAQ: KROS) Keros Therapeutics's forecast annual revenue growth rate of -46.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Keros Therapeutics's revenue in 2025 is $214,713,000.On average, 5 Wall Street analysts forecast KROS's revenue for 2025 to be $8,894,775,666, with the lowest KROS revenue forecast at $8,580,006,208, and the highest KROS revenue forecast at $9,390,283,717. On average, 2 Wall Street analysts forecast KROS's revenue for 2026 to be $1,076,308,471, with the lowest KROS revenue forecast at $528,000,382, and the highest KROS revenue forecast at $1,624,616,560.
In 2027, KROS is forecast to generate $1,320,000,955 in revenue, with the lowest revenue forecast at $609,231,210 and the highest revenue forecast at $2,030,770,700.